22,060 Shares in Neurogene Inc. $NGNE Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new stake in Neurogene Inc. (NASDAQ:NGNE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,060 shares of the company’s stock, valued at approximately $694,000. Seven Fleet Capital Management LP owned approximately 0.11% of Neurogene at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Neurogene in the 2nd quarter valued at about $31,000. Legal & General Group Plc acquired a new position in Neurogene during the 2nd quarter worth approximately $35,000. BNP Paribas Financial Markets boosted its holdings in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Neurogene in the fourth quarter worth approximately $66,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after acquiring an additional 1,059 shares during the period. Institutional investors and hedge funds own 52.37% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on NGNE shares. Canaccord Genuity Group decreased their price objective on Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. HC Wainwright reduced their price target on shares of Neurogene from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Rodman & Renshaw started coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price target for the company. Finally, Guggenheim upped their price objective on shares of Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Neurogene Stock Performance

Shares of NGNE opened at $38.60 on Friday. The stock has a 50 day moving average price of $36.47 and a two-hundred day moving average price of $29.01. The firm has a market capitalization of $772.39 million, a P/E ratio of -7.67 and a beta of 1.69. Neurogene Inc. has a 52 week low of $15.93 and a 52 week high of $43.66.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.42) by ($0.11). On average, equities analysts forecast that Neurogene Inc. will post -5.62 earnings per share for the current year.

Insider Buying and Selling

In other Neurogene news, CFO Christine Cvijic sold 4,200 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the transaction, the chief financial officer directly owned 84,040 shares in the company, valued at approximately $3,036,365.20. This trade represents a 4.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 9,600 shares of company stock valued at $339,932. Corporate insiders own 11.68% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.